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OBJECTIVE: To report initial experience from the use of extracorporeal membrane oxygenation (ECMO) in
patients who received lung transplantation.
METHODS: Retrospective study of a single tertiary center in the Brazilian state of São Paulo, a national reference
in lung transplantation, based on the prospective collection of data from electronic medical records. The period
analyzed extended from January 2009 (beginning of the program) until December 2018.
RESULTS: A total of 75 lung transplants were performed, with ECMO used in 8 (10.7%) cases. Of the patients,
4 (50%) were female. The mean age was 46.4±14.3 years. The causes of the end-stage lung disease that led to
transplantation were pulmonary arterial hypertension in 3 (37.5%) patients, bronchiectasis in 2 (25%) patients,
pulmonary fibrosis in 2 (25%) patients, and pulmonary emphysema in 1 (12.5%) patient. In our series, 7 (87.5%)
cases were sequential bilateral transplantations. Prioritization was necessary in 4 (50%) patients, and in
1 patient, ECMO was used as a bridge to transplantation. The ECMO route was central in 4 (50%), peripheral
venovenous in 2 (25%) and peripheral venoarterial in 2 (25%) patients. The mean length of the intensive care
unit (ICU) stay was 14±7.5 days and of the hospital stay was 34.1±34.2 days. The mean ECMO duration was
9.3±6.6 days with a 50% decannulation rate. Three patients were discharged (37.5%).
CONCLUSION: Lung transplantation requires complex treatment, and ECMO has allowed extending the
indications for transplantation and provided adjuvant support in the clinical management of these patients.
KEYWORDS: Lung Transplantation; Extracorporeal Membrane Oxygenation; Hypertension, Pulmonary; Pul-
monary Fibrosis; Heart Failure; Diastolic.
’ INTRODUCTION
Lung transplantation is a treatment alternative for end-
stage lung diseases. According to the International Society of
Heart and Lung Transplantation (ISHLT), the number of trans-
plants and survival have both increased over the years (1).
Additionally, patient complexity has also increased. During
the same period, there has been a concomitant appearance of
new technologies in thoracic surgery that have led to new
patient support techniques, such as ex vivo lung perfusion (2),
reconditioning of borderline lungs and donor lungs after
cardiac death, and extracorporeal membrane oxygenation
(ECMO) (3,4).
ECMO is a complex advanced life support technique that
allows maintaining blood gas exchange (carbon dioxide
removal and oxygenation) and long-term cardiocirculatory
support, temporarily replacing the heart and lungs (5). ECMO
in lung transplantation has been used for the treatment of
primary graft dysfunction (PGD), as a bridge to transplanta-
tion and cardiocirculatory support during surgery, replacing
extracorporeal circulation, to help manage hemodynamic
instability in the postoperative period (3).
The objective of this study is to report the initial experience
of the use of ECMO in a tertiary center that is a national
reference for lung transplantation.
’ MATERIALS AND METHODS
Study design
This is a retrospective study of a single tertiary center, a
national reference for lung transplantation, in the state of São
Paulo, Brazil, based on the prospective collection of dataDOI: 10.6061/clinics/2020/e1698
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from electronic medical records of said hospital. The period
of analysis was from January 2009 (beginning of the pro-
gram) to December 2018. This study was approved by
the Research Ethics Committee of Hospital Israelita Albert
Einstein, Brazil (approval number 22934919.5.0000.0071),
and was performed in accordance with the ethical stan-
dards of the Brazilian National Research Ethics Commission
and their subsequent amendments.
All patients undergoing lung transplantation who at
some point needed ECMO were included. The investigated
variables were the recipient characteristics, intraoperative
data, and morbidity and mortality outcomes. There were no
exclusion criteria. During this period, the surgical technique
and immunosuppression protocol remained the same.
In all cases, ECMO was instituted by the hospital’s lung
transplant team, who was trained according to the recom-
mendations of the Extracorporeal Life Support Organization
(ELSO) (6). The team’s perfusionists helped with adjusting
the circuit parameters and controlling the activated coagula-
tion time (ACT). Heparin was titrated to keep ACT between
180 and 240 seconds, and an additional blood product was
used when necessary. Venovenous (VV) ECMO was insti-
tuted using the Seldinger technique, with the drainage
cannula placed in the right common femoral vein and the
return cannula in the right internal jugular vein. Peripheral
venoarterial (VA) ECMO was instituted using the Seldinger
technique, with the drainage cannula placed in the right
common femoral vein and the return cannula in the left
femoral artery. In all cases, we installed a distal perfusion
cannula in the femoral artery. In central ECMO, the drainage
cannula was placed in the right atrium and the return
cannula in the ascending aorta. In these cases, the arterial
flow was calculated based on the body surface area, with a
target of 70% of the nominal flow, and was corrected, when
necessary, based on the hemodynamic and metabolic demand
during the procedure monitoring the arterial and venous
pressure and the circuit pressure. The cell saver system was
used during surgery. We used a centrifugal magnetic pump
with a polymethylpentene oxygenator membrane (Rota-
flow/Quadrox-ID, Getinge Cardiopulmonary AG, Hirrlinger,
Germany). In all cases, the positions of the cannulae were
checked by transesophageal echocardiography or chest
X- ray/fluoroscopy.
Statistical analysis
Quantitative data were analyzed using descriptive statis-
tics and are expressed as means and standard deviations
(±SD). Qualitative variables are expressed as frequencies
and percentages. Statistical modeling and testing were per-
formed with SPSS version 21.0.
’ RESULTS
Recipient profile
A total of 75 lung transplants were performed, of which
ECMO was used in 8 (10.7%) cases. Of the patients, 4 (50%)
were female. The mean age of the patients was 46.4±
14.3 years, the mean time on the waiting list was 708.5±
442.2 days, the mean systolic pulmonary artery pressure was
55.4±23.8 mmHg. The diagnoses of end-stage lung diseases
that led to transplantation were pulmonary hypertension
in 3 (37.5%) patients, bronchiectasis in 2 (25%) patients,
pulmonary fibrosis in 2 (25%) patients, and pulmonary
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Lung transplantation characteristics
In our series, 7 (87.5%) cases were bilateral sequential
transplants, of which 6 were left-right, with an ischemia time
of the first side of 266.2±47.8 minutes and of the second side
of 395±42.3 minutes. Prioritization (when we asked the state
technical transplant agency to make priority for a transplant)
was necessary in 4 (50%) patients, and in 1 patient, ECMO
was used as a bridge to transplantation. The use of a cardio-
pulmonary bypass (CPB) was necessary in only 1 case
(Table 1). The mean number of the transfused packed red
blood cells was 1.7±1.2 bags. Tracheostomy was necessary
in 4 (50%) patients.
ECMO data
Regarding the time of ECMO initiation, it was used as a
bridge to lung transplantation in only in 1 (12.5%) patient,
during the surgery in 5 (62.5%) patients and postoperatively
in 2 (25%) patients. The ECMO route was central in 4 (50%)
patients, peripheral VV in 2 (25%) patients and peripheral VA
in 2 (25%) patients. The ECMO route was changed in 3 (37.5%)
patients; of the patients on central ECMO, 2 were switched to
VV ECMO, after cardiocirculatory stability, and 1 was switched
to VA ECMO and later to VV ECMO, for a total of 18 days on
ECMO, after which the patient was decannulated. The mean
ECMO duration was 9.3±6.6 days with a 50% decannulation
rate, i.e., 4 patients. The mean length of the intensive care
unit (ICU) stay was 14±7.5 days and of the hospital stay was
34.1±34.2 days. Regarding outcomes, 5 (62.5%) patients died
during the same hospital stay, and 3 (37.5%) patients were
discharged. Emergency ECMO was instituted in 2 (25%) cases.
The reasons ECMO was required were pulmonary hyperten-
sion in 4 (50%) patients, hemodynamic instability in 2 (25%)
patients, PGD in 1 (12.5%) patient and respiratory failure
1 (12.5%) patient. Renal replacement therapy was required in
6 (75%) cases. Complications secondary to ECMO were acute
arterial occlusion requiring surgical intervention in 3 patients
(37.5%), neurological events in 2 (25%) patients, deep venous
thrombosis in 1 (12.5%) patient and major perioperative
bleeding in 2 (25%) patients (Table 2).
’ DISCUSSION
Lung transplantation is a treatment alternative for advanced
lung diseases, such as obstructive, restrictive, and vascular lung
disease and suppurations such as bronchiectasis. However,
organ availability is scarce, and the recipient waiting list is
growing. Because lung disease tends to be severe and pro-
gressive, increased waiting times for transplantation result in
increased procedural morbidity and mortality (7).
In this context, ECMO as respiratory and/or cardiocircu-
latory support can be used as a tool to assist this population.
The first use of ECMO in 1972 by Dr. Donald Hill as extra-
corporeal life support sparked the idea of using this techno-
logy (3). However, ECMO gained prominence in the treatment
of acute respiratory distress syndrome (ARDS) in 2009 with the
Conventional ventilation or ECMO for Severe Adult Respira-
tory failure (CESAR) Trial due to the H1N1 epidemic, and since
then, there has been an increase in its use (8).
PGD, an early reperfusion acute lung injury in lung
transplantation, mimics ARDS in cases of infection, and this
phenomenon has an impact on morbidity and mortality in
transplant recipients (9). PGD has an incidence between 15
and 57%, and 30-day mortality that can reach 24.5% in grade
III PGD. The use of ECMO can be safely sustained until
transplanted lungs have time to recover. In our series, ECMO
was used in 1 (12.5%) patient for the treatment of PGD. The
ECMO modality used is VV because the patient has res-
piratory failure but normal cardiac function (10).
ECMO can be used as a bridge to lung transplantation.
Patients who are on the waiting list for transplantation can
experience significant clinical worsening, leading to the
inability of the lungs to perform their functions. In this case,
ECMO is instituted to stabilize the clinical picture, and the
patient is prioritized for transplantation (11). In our series,
half of the patients were prioritized, of which ECMO was
instituted as a bridge to lung transplantation in 1 (12.5%).
One of the advantages of using ECMO as a bridge to lung
transplantation is the possibility of maintaining it in place
during and after surgery, guaranteeing ventilatory support
and allowing protective mechanical ventilation (12).
Lung transplantation in patients with pulmonary hyper-
tension poses challenges because there are technical difficul-
ties and a higher rate of complications when compared to
other patient groups. However, despite high mortality in the
first year, lung transplantation offers a better long-term
prognosis, worse only than in patients with cystic fibrosis (1).
As a result of cardiac remodeling and right ventricular
dysfunction, sometimes with compromised left ventricular
function, bilateral or cardiopulmonary transplantation is the
procedure of choice. Intraoperative cardiopulmonary care in
these cases is mandatory, even in cases of bilateral sequential
transplantation. One of the great advantages of ECMO over

















Patient 1 VV 8 Yes 24 24 Yes Mesenteric ischemia
Patient 2 Central 2 No 2 2 Yes Intraoperative bleeding and stroke
Patient 3 Central 2 PO VV 2 Yes 4 4 Yes Sepsis
Patient 4 Central 16 PO VV 18 Yes 18 18 Yes Stroke
Patient 5 VA
Peripheral
5 Yes 14 115 No Alive Intraoperative bleeding/Occlusion
arterial/Acute abdominal perforation
Patient 6 Central VA/VV 18 Yes 18 18 Yes Occlusion arterial
Patient 7 VA
Peripheral
7 No 18 47 No Alive Occlusion arterial
Patient 8 VV 14 Yes 14 45 No Alive Venous thrombosis of a lower limb
Abbreviations: VA: venoarterial; VV: venovenous; PO: postoperative day.
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CPB is the possibility of being instituted before transplanta-
tion as a bridge and of being maintained after the procedure.
Studies show that maintaining ECMO in the postoperative
period in patients who underwent lung transplantation is
associated with better survival, especially in the pulmonary
arterial hypertension subgroup (13). Additionally, less anti-
coagulation and priming volume are necessary compared
with those of conventional CPB. Studies have shown that
ECMO is associated with a shorter length of ICU and
hospital stays and lower rates of hemodialysis and reintuba-
tion compared with those of CPB (14), and currently, some
transplant centers use ECMO as the first choice for circu-
latory care (15). In our series, 4 (50%) patients underwent
transplantation due to pulmonary hypertension, of which
the underlying diseases were idiopathic pulmonary hyper-
tension in 2 patients, veno-occlusive pulmonary hyperten-
sion in 1 patient and pulmonary hypertension secondary
to bronchiectasis due to cystic adenomatosis in 1 patient.
In these cases, ECMO was initiated during the surgical
procedure.
ELSO has developed guidelines that describe the ideal
institutional requirements for the development of an ECMO
program (6). Moll et al. described how to develop and imple-
ment an ECMO team in a hospital, motivated by unsatisfactory
outcomes. After the implementation of the program, initial data
showed that 53.3% of patients were decannulated (16), while
in our service, the rate of decannulation was 50%. Regarding
hospital discharge, only 40% of the patients in the study by
Moll et al. were discharged from the hospital, whereas in our
series, the rate was 37.5%; the mean ECMO duration was
4.8±3.9 days, and in our series, it was 14±7.5 days. A Korean
study showed that the rate of postoperative decannulation
failure after lung transplantation was 43.2%, causing longer
ICU stays (16 days) than those in the decannulated group
(6 days) (po0.001); in the study, young donors with a high
PO2/FiO2 ratio and short surgery time were factors that
contributed to decannulation (17).
In our series, 6 (75%) patients required hemodialysis at
some time during hospitalization. Banga et al. conducted a
study using the UNOS database, correlating predictive factors
for early hemodialysis after lung transplantation. Among
these predictors, the use of preoperative ECMO (10.4%),
mechanical ventilation (18.8%) and pulmonary hypertension
(27.8%) were the most important (18). Another study using
the UNOS database for patients who required ECMO after
lung transplantation showed a greater risk for postoperative
dialysis (hazard ratio [HR] 6.476, po0.001) (19).
Studies have shown that ECMO has a lower risk of
complications than does CPB. However, several complica-
tions are related to ECMO: neurological complications;
bleeding at the puncture site; infection; bleeding such as
digestive hemorrhage, hemothorax, and epistaxis; thrombo-
cytopenia; and arterial occlusion. The most prevalent is
bleeding, ranging from 5 to 79% in the literature. The cause is
multifactorial but also secondary to iatrogenic anticoagula-
tion. Arterial occlusion of the limb varies between 13-25% in
the literature, while in our series, it was 37.5% (3,12,20). All
patients underwent open embolectomy without other com-
plications or sequelae.
’ CONCLUSIONS
Lung transplantation requires complex treatment, and ECMO
has allowed extending the indications for transplantation
and provided adjuvant support in the clinical management
of these patients. However, it is a technology that requires a
team trained according to the guidelines of the governing
organization because patients requiring ECMO are severely
ill and manifest complications that, although treatable, must
be strictly managed.
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